SCHEMBL26123722

SCHEMBL26123722

COC(=O)C1(Oc2ccccc2Br)CC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 3/20 0.38
LY96 Q9Y6Y9 1/20 0.38
RAB9A P51151 5/20 0.36
NPC1 O15118 2/20 0.36
GRM4 Q14833 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
KCNA3 P22001 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15397098 0.83 ADAM17 (0.40) KMT2ASMN1; SMN2HTTLMNAHPGD
SCHEMBL26126678 0.82 HPGD (0.40) KMT2ASMN1; SMN2HTTLMNAHPGD
SCHEMBL25201271 0.82 GPR119 (0.47) LMNAKDM4EALDH1A1
SCHEMBL27094519 0.80 MEN1 (0.37) KMT2AHTTHPGDMEN1GRM4
SCHEMBL31645176 0.80 KMT2A (0.37) KMT2ASMN1; SMN2HPGDMEN1RAB9A
SCHEMBL20182572 0.80 ALDH1A1 (0.43) KMT2ASMN1; SMN2HTTLMNAHPGD
SCHEMBL26124155 0.78 MEN1 (0.43) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL31421785 0.78 MEN1 (0.43) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL18322694 0.78 CYP2D6 (0.40) KMT2AHPGDMEN1NPC1KDM4E
SCHEMBL4114043 0.78 HDAC4 (0.42) KMT2AHPGDMEN1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188037-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICALS CO (JP) 2025-06-12 US disclosed
WO-2025074305-A1 N-(1-(AMINOMETHYL)CYCLOPROPYL)(ARYL OR HETEROARYL) CARBOXAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-04-10 WO disclosed
CN-119585238-A N- (pyrrolidin-3-yl or piperidin-4-yl) acetamide derivatives 武田药品工业株式会社 2025-03-07 CN disclosed
EP-4499224-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2025-02-05 EP disclosed
WO-2023187677-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-05 WO disclosed
WO-2023187677-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188037-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES SSTR4, SSTR3, SSTR1 KMT2A 4505/4885SMN1; SMN2 322/4885HTT 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.